FR2802097B1 - Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication - Google Patents

Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication

Info

Publication number
FR2802097B1
FR2802097B1 FR9915763A FR9915763A FR2802097B1 FR 2802097 B1 FR2802097 B1 FR 2802097B1 FR 9915763 A FR9915763 A FR 9915763A FR 9915763 A FR9915763 A FR 9915763A FR 2802097 B1 FR2802097 B1 FR 2802097B1
Authority
FR
France
Prior art keywords
mucosa
suspension
composition
solution
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9915763A
Other languages
English (en)
French (fr)
Other versions
FR2802097A1 (fr
Inventor
Jack Auzerie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INVEST S THERAPEUTIQUES ESSAIS
Original Assignee
INVEST S THERAPEUTIQUES ESSAIS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9915763A priority Critical patent/FR2802097B1/fr
Application filed by INVEST S THERAPEUTIQUES ESSAIS filed Critical INVEST S THERAPEUTIQUES ESSAIS
Priority to JP2001544659A priority patent/JP2003516957A/ja
Priority to PCT/FR2000/003533 priority patent/WO2001043720A1/fr
Priority to AT00988913T priority patent/ATE336987T1/de
Priority to US10/149,695 priority patent/US20030091642A1/en
Priority to CA002394416A priority patent/CA2394416A1/fr
Priority to PT00988913T priority patent/PT1237537E/pt
Priority to AU25256/01A priority patent/AU2525601A/en
Priority to ES00988913T priority patent/ES2270895T3/es
Priority to DE60030319T priority patent/DE60030319T2/de
Priority to EP00988913A priority patent/EP1237537B1/fr
Priority to DK00988913T priority patent/DK1237537T3/da
Publication of FR2802097A1 publication Critical patent/FR2802097A1/fr
Application granted granted Critical
Publication of FR2802097B1 publication Critical patent/FR2802097B1/fr
Priority to CY20061101679T priority patent/CY1106249T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Steroid Compounds (AREA)
FR9915763A 1999-12-14 1999-12-14 Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication Expired - Fee Related FR2802097B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR9915763A FR2802097B1 (fr) 1999-12-14 1999-12-14 Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
EP00988913A EP1237537B1 (fr) 1999-12-14 2000-12-14 Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
AT00988913T ATE336987T1 (de) 1999-12-14 2000-12-14 Gelzubereitung enthaltend einen gelösten oder suspendierten wirkstoff,insbesondere zur anwendung auf einer schleimhaut und herstellungsverfahren
US10/149,695 US20030091642A1 (en) 1999-12-14 2000-12-14 Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof
CA002394416A CA2394416A1 (fr) 1999-12-14 2000-12-14 Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
PT00988913T PT1237537E (pt) 1999-12-14 2000-12-14 Composição sob a forma de gel destinada a receber um princípio activo em solução ou em suspensão, nomeadamente para aplicação sobre uma mucosa e processo de produção
JP2001544659A JP2003516957A (ja) 1999-12-14 2000-12-14 特に粘膜塗布用の溶液又は懸濁状の有効成分を入れるためのゲル形状組成物及び製造方法
ES00988913T ES2270895T3 (es) 1999-12-14 2000-12-14 Composicion en forma de gel destinada a recibir un principio activo o en suspension, en particular para la aplicacion sobre una mucosa y procedimiento de fabricacion.
DE60030319T DE60030319T2 (de) 1999-12-14 2000-12-14 Gelzubereitung enthaltend einen gelösten oder suspendierten wirkstoff,insbesondere zur anwendung auf einer schleimhaut und herstellungsverfahren
PCT/FR2000/003533 WO2001043720A1 (fr) 1999-12-14 2000-12-14 Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
DK00988913T DK1237537T3 (da) 1999-12-14 2000-12-14 Præparat i form af en gel til modtagelse af et aktivt stof i oplösning eller suspension, især til anvendelse på en slimhinde, og fremgangsmåde til dets fremstilling
AU25256/01A AU2525601A (en) 1999-12-14 2000-12-14 Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof
CY20061101679T CY1106249T1 (el) 1999-12-14 2006-11-16 Συνθεση υπο τη μορφη πηκτωματος προβλεπομενη ωστε να δεχεται ενα δραστικο παραγοντα σε διαλυση ή εναιωρηση ειδικα για εφαρμογη επι ενος βλεννογονου και μεθοδος παρασκευης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9915763A FR2802097B1 (fr) 1999-12-14 1999-12-14 Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication

Publications (2)

Publication Number Publication Date
FR2802097A1 FR2802097A1 (fr) 2001-06-15
FR2802097B1 true FR2802097B1 (fr) 2002-12-13

Family

ID=9553244

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9915763A Expired - Fee Related FR2802097B1 (fr) 1999-12-14 1999-12-14 Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication

Country Status (13)

Country Link
US (1) US20030091642A1 (https=)
EP (1) EP1237537B1 (https=)
JP (1) JP2003516957A (https=)
AT (1) ATE336987T1 (https=)
AU (1) AU2525601A (https=)
CA (1) CA2394416A1 (https=)
CY (1) CY1106249T1 (https=)
DE (1) DE60030319T2 (https=)
DK (1) DK1237537T3 (https=)
ES (1) ES2270895T3 (https=)
FR (1) FR2802097B1 (https=)
PT (1) PT1237537E (https=)
WO (1) WO2001043720A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031640A1 (it) 2003-08-08 2005-02-09 Mipharm S P A Base per gel bioadesivi.
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
AU2004274000B2 (en) * 2003-09-19 2009-07-30 Drugtech Corporation Pharmaceutical delivery system
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
CA2605341A1 (en) * 2005-05-09 2006-11-16 Drugtech Corporation Modified-release pharmaceutical compositions
CN101374501A (zh) * 2006-01-05 2009-02-25 药物技术公司 组合物及其使用方法
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
JP2533723B2 (ja) * 1992-12-28 1996-09-11 東興薬品工業株式会社 速乾性ゲルタイプ手指消毒剤
ES2078175B1 (es) * 1993-12-31 1996-10-16 Cusi Lab Formulacion farmaceutica conteniendo clobetasona y tobramicina y sus aplicaciones.
US5902110A (en) * 1995-12-18 1999-05-11 The Block Drug Company Bone regeneration
US5869601A (en) * 1996-04-05 1999-02-09 S. C. Johnson & Son, Inc. Method of stabilizing the viscosity of a thickened composition
EP1011609A4 (en) * 1997-05-09 2000-08-16 Medlogic Global Corp COMPOSITIONS FOR COSMETIC APPLICATIONS
US7064114B2 (en) * 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations

Also Published As

Publication number Publication date
ES2270895T3 (es) 2007-04-16
CA2394416A1 (fr) 2001-06-21
PT1237537E (pt) 2007-01-31
DE60030319T2 (de) 2007-08-30
EP1237537B1 (fr) 2006-08-23
ATE336987T1 (de) 2006-09-15
FR2802097A1 (fr) 2001-06-15
DK1237537T3 (da) 2006-12-27
AU2525601A (en) 2001-06-25
JP2003516957A (ja) 2003-05-20
EP1237537A1 (fr) 2002-09-11
US20030091642A1 (en) 2003-05-15
WO2001043720A1 (fr) 2001-06-21
CY1106249T1 (el) 2011-06-08
DE60030319D1 (de) 2006-10-05

Similar Documents

Publication Publication Date Title
TR200103493T2 (tr) Metaloproteaz önleyicileri
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
TR200002191T2 (tr) Potasyum kanal önleyicileri
EP0931788A3 (en) Metalloprotease inhibitors
BR0010220A (pt) Compostos de pirimidinona
CA2388646A1 (en) Methods and compositions utilizing quinazolinones
MA26629A1 (fr) Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production
AU5850200A (en) Positive plate active material, method for producing the same, and secondary cell
CA2387873A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
CA2374003A1 (en) Improved cellular uptake of bioactive agents
FR2774288B1 (fr) Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
ATE346090T1 (de) Abgeschwaechte mikroorganismen fuer die behandlung von infektionen
BR0008309A (pt) Processo de criar uma superfìcie de concreto com padrão com o auxìlio de um agente retardador de superfìcie de concreto
TR200002248T2 (tr) Yeni dihidroksiheksanoik asit türevleri
FR2802097B1 (fr) Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
GB9619660D0 (en) Prevention of gastrointestinal damage
WO2000042987A3 (en) Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
AU3386199A (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
WO2000069841A3 (en) Benzofuranylaminoalcohols
WO2000048584A3 (en) Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain
CA2262582A1 (en) Hcg and derivatives as matrix metalloproteases inhibitors
WO2001022917A3 (en) Effervescent compositions comprising nimesulide
ITMI911877A1 (it) Enzimi fibrinolitici ammidati e loro precursori, e processi per la loro preparazione.
TR199901546A2 (xx) Pirolidinil hidroksamik asid bile�imleri i�in y�ntem.

Legal Events

Date Code Title Description
TQ Partial transmission of property
TQ Partial transmission of property
CD Change of name or company name
ST Notification of lapse

Effective date: 20081020